|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Abal M, Llaurado M, Doll A, et al:
Molecular determinants of invasion in endometrial cancer. Clin
Transl Oncol. 9:272–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mylonas I, Makovitzky J, Richter DU,
Jeschke U, Briese V and Friese K: Cathepsin D expression in normal,
hyperplastic and malignant endometrial tissue: an
immunohistochemical analysis. Acta Histochem. 105:245–252. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aglund K, Rauvala M, Puistola U, et al:
Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9
correlates to the grade and the stage. Gynecol Oncol. 94:699–704.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanseverino F, Santopietro R, Torricelli
M, et al: pRb2/p130 and VEGF expression in endometrial carcinoma in
relation to angiogenesis and histopathologic tumor grade. Cancer
Biol Ther. 5:84–88. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Santin AD, Diamandis EP, Bellone S, et al:
Human kallikrein 6: a new potential serum biomarker for uterine
serous papillary cancer. Clin Cancer Res. 11:3320–3325. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roshy S, Sloane BF and Moin K:
Pericellular cathepsin B and malignant progression. Cancer
Metastasis Rev. 22:271–286. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nasu K, Kai K, Fujisawa K, Takai N,
Nishida Y and Miyakawa I: Expression of cathepsin L in normal
endometrium and endometrial cancer. Eur J Obstet Gynecol Reprod
Biol. 99:102–105. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vasiljeva O and Turk B: Dual contrasting
roles of cysteine cathepsins in cancer progression: apoptosis
versus tumour invasion. Biochimie. 90:380–386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sinha AA, Jamuar MP, Wilson MJ, Rozhin J
and Sloane BF: Plasma membrane association of cathepsin B in human
prostate cancer: biochemical and immunogold electron microscopic
analysis. Prostate. 49:172–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jedeszko C and Sloane BF: Cysteine
cathepsins in human cancer. Biol Chem. 385:1017–1027. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Victor BC, Anbalagan A, Mohamed MM, Sloane
BF and Cavallo-Medved D: Inhibition of cathepsin B activity
attenuates extracellular matrix degradation and inflammatory breast
cancer invasion. Breast Cancer Res. 13:R1152011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Q, Fei J, Wu L, et al: Detection of
cathepsin B, cathepsin L, cystatin C, urokinase plasminogen
activator and urokinase plasminogen activator receptor in the sera
of lung cancer patients. Oncol Lett. 2:693–699. 2011.PubMed/NCBI
|
|
14
|
Talieri M, Papadopoulou S, Scorilas A, et
al: Cathepsin B and cathepsin D expression in the progression of
colorectal adenoma to carcinoma. Cancer Lett. 205:97–106. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scorilas A, Fotiou S, Tsiambas E, et al:
Determination of cathepsin B expression may offer additional
prognostic information for ovarian cancer patients. Biol Chem.
383:1297–1303. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Devetzi M, Scorilas A, Tsiambas E, et al:
Cathepsin B protein levels in endometrial cancer: potential value
as a tumour biomarker. Gynecol Oncol. 112:531–536. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Creasman W: Revised FIGO staging for
carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu D, Wang H, Li Z, et al: Cathepsin B may
be a potential biomarker in cervical cancer. Histol Histopathol.
27:79–87. 2012.PubMed/NCBI
|
|
19
|
Kyo S, Sakaguchi J, Ohno S, et al: High
Twist expression is involved in infiltrative endometrial cancer and
affects patient survival. Hum Pathol. 37:431–438. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sato R, Jobo T and Kuramoto H: Parametrial
spread is a prognostic factor in endometrial carcinoma. Eur J
Gynaecol Oncol. 24:241–245. 2003.PubMed/NCBI
|
|
22
|
Jedinak A and Maliar T: Inhibitors of
proteases as anticancer drugs. Neoplasma. 52:185–192.
2005.PubMed/NCBI
|
|
23
|
Hornebeck W, Emonard H, Monboisse JC and
Bellon G: Matrix-directed regulation of pericellular proteolysis
and tumor progression. Semin Cancer Biol. 12:231–241. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bradley WH, Lima PH, Rodgers L, Blomquist
CH and Downs LS: Endometrial carcinoma expresses an increased
cathepsin B/D ratio. Gynecol Oncol. 108:84–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gopinathan A, Denicola GM, Frese KK, et
al: Cathepsin B promotes the progression of pancreatic ductal
adenocarcinoma in mice. Gut. 61:877–884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nomura T and Katunuma N: Involvement of
cathepsins in the invasion, metastasis and proliferation of cancer
cells. J Med Invest. 52:1–9. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shiose Y, Ochi Y, Kuga H, Yamashita F and
Hashida M: Relationship between drug release of DE-310,
macromolecular prodrug of DX-8951f, and cathepsins activity in
several tumors. Biol Pharm Bull. 30:2365–2370. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sloane BF, Yan S, Podgorski I, et al:
Cathepsin B and tumor proteolysis: contribution of the tumor
microenvironment. Semin Cancer Biol. 15:149–157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vasiljeva O, Korovin M, Gajda M, et al:
Reduced tumour cell proliferation and delayed development of
high-grade mammary carcinomas in cathepsin B-deficient mice.
Oncogene. 27:4191–4199. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van der Stappen JW, Williams AC, Maciewicz
RA and Paraskeva C: Activation of cathepsin B, secreted by a
colorectal cancer cell line requires low pH and is mediated by
cathepsin D. Int J Cancer. 67:547–554. 1996.PubMed/NCBI
|
|
31
|
Skrzydlewska E, Sulkowska M, Koda M and
Sulkowski S: Proteolytic-antiproteolytic balance and its regulation
in carcinogenesis. World J Gastroenterol. 11:1251–1266. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mason SD and Joyce JA: Proteolytic
networks in cancer. Trends Cell Biol. 21:228–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Caglic D, Pungercar JR, Pejler G, Turk V
and Turk B: Glycosaminoglycans facilitate procathepsin B activation
through disruption of propeptide-mature enzyme interactions. J Biol
Chem. 282:33076–33085. 2007. View Article : Google Scholar : PubMed/NCBI
|
